[HTML][HTML] Unravelling similarities and differences in the role of circular and linear PVT1 in cancer and human disease
D Traversa, G Simonetti, D Tolomeo, G Visci… - British journal of …, 2022 - nature.com
The plasmacytoma variant translocation 1 (PVT1) is a long non-coding RNA gene involved
in human disease, mainly in cancer onset/progression. Although widely analysed, its …
in human disease, mainly in cancer onset/progression. Although widely analysed, its …
[HTML][HTML] The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma
T Lu, J Zhang, ZY Xu-Monette, KH Young - Experimental Hematology & …, 2023 - Springer
Diffuse large B-cell lymphoma (DLBCL) can be cured with standard front-line
immunochemotherapy, whereas nearly 30–40% of patients experience refractory or relapse …
immunochemotherapy, whereas nearly 30–40% of patients experience refractory or relapse …
The impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC
B Collinge, S Ben-Neriah, L Chong… - Blood, The Journal …, 2021 - ashpublications.org
Abstract When the World Health Organization defined high-grade B-cell lymphoma with
MYC and BCL2 and/or BCL6 rearrangements (HGBL-DH/TH) as a clinical category …
MYC and BCL2 and/or BCL6 rearrangements (HGBL-DH/TH) as a clinical category …
[HTML][HTML] 伴MYC、 BCL2 和（ 或） BCL6 重排的高级别B 细胞淋巴瘤在弥漫大B 细胞淋巴瘤中的发生率
李敏， 张秋露， 赵炜， 黄欣， 宫丽平… - Chinese Journal of …, 2021 - ncbi.nlm.nih.gov
伴MYC、BCL2和（或）BCL6重排的高级别B细胞淋巴瘤在弥漫大B细胞淋巴瘤中的发生率- PMC
Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …
Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …
[HTML][HTML] Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients
Double/triple hit lymphoma (DH/TH), known as high-grade B-cell lymphoma (HGBL), is an
aggressive diffuse large B cell lymphoma (DLBCL), defined as having concurrent MYC …
aggressive diffuse large B cell lymphoma (DLBCL), defined as having concurrent MYC …
[HTML][HTML] Epigenetic mechanisms in canine cancer
PLP Xavier, S Müller, H Fukumasu - Frontiers in oncology, 2020 - frontiersin.org
A plethora of data has highlighted the role of epigenetics in the development of cancer.
Initiation and progression of different cancer types are associated with a variety of changes …
Initiation and progression of different cancer types are associated with a variety of changes …
[HTML][HTML] Copy number alteration and mutational profile of high-grade b-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, diffuse Large b-cell …
M Miyaoka, YY Kikuti, J Carreras, A Ito, H Ikoma… - Cancers, 2022 - mdpi.com
Simple Summary Diffuse large B-cell lymphoma (DLBCL) is one of the most frequent non-
Hodgkin lymphomas. DLBCL with MYC alteration is classified as (1) high-grade B-cell …
Hodgkin lymphomas. DLBCL with MYC alteration is classified as (1) high-grade B-cell …
[HTML][HTML] Evolving insights into the genomic complexity and immune landscape of diffuse large B-cell lymphoma: opportunities for novel biomarkers
S El Hussein, KRM Shaw, F Vega - Modern Pathology, 2020 - Elsevier
Recently, comprehensive genomic analyses have allowed a better molecular
characterization of diffuse large B-cell lymphoma (DLBCL), offering novel opportunities in …
characterization of diffuse large B-cell lymphoma (DLBCL), offering novel opportunities in …
[HTML][HTML] Clinicopathological characteristics and MYC status determine treatment outcome in plasmablastic lymphoma: a multi-center study of 76 consecutive patients
HM Witte, N Hertel, H Merz, HW Bernd, V Bernard… - Blood cancer …, 2020 - nature.com
Dear Editor, Plasmablastic lymphoma (PBL) is a rare and aggressive B-cell disorder of post-
germinal centre origin with features intermediate between high-grade B-cell lymphoma and …
germinal centre origin with features intermediate between high-grade B-cell lymphoma and …
MiR-665 suppresses the progression of diffuse large B cell lymphoma (DLBCL) through targeting LIM and SH3 protein 1 (LASP1)
Y Wang, D Guo, B Li, Y Wang, B Wang, Z Wang… - Leukemia Research, 2022 - Elsevier
Diffuse large B cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma
worldwide, is aggressive and highly heterogeneous. MiR-665 was found to be lowly …
worldwide, is aggressive and highly heterogeneous. MiR-665 was found to be lowly …